Podcast
MSL Talk: Tom Caravela, Mike Penkethman
How and Why Medical Affairs Can Support Diversity in Clinical Trials
Summary
In this episode, Tom Caravela is joined by Brad Atkinson, Brian Wilson, and Christina Wright to explore the critical role of diversity in clinical trials and the MSL’s part in fostering inclusivity. The discussion covers FDA guidance on diversity, challenges in therapeutic areas, and the importance of patient-centric approaches. The speakers delve into the strategic roles of MSLs in education and the historical context of diversity in clinical trials. They provide actionable strategies for field medical teams to enhance trial diversity and emphasize the significance of cultural awareness and allyship. The episode concludes with reflections and a call to action for promoting diversity in medical settings.
Christina Wright, Brad Atkinson and Brian Wilson discuss the important role Medical Affairs/MSLs can play in supporting diversity in clinical trials
The group discusses…
👉 Why does medical affairs need to be involved in diversity clinical trial initiatives?
👉 How can field medical get comfortable with the D and I conversation?
👉 What resources can be helpful
👉 3 Pillars of “Allyship”
👉 Why insights are currency
diversity in clinical trials, role of MSLs, FDA guidance on diversity, patient-centric approaches, cultural awareness and allyship
Related Topics
You May Also Like
MSL Talk: Tom Caravela, Mike Penkethman
Article
Laleh Amiri-Kordestani & Richard Pazdur
Oncology approvals in 2020: a year of firsts in the midst of a pandemic
Article
Haiqing Isaac Dai, Yulia Vugmeyster, Naveen Mangal
Characterizing Exposure–Response Relationship for Therapeutic Monoclonal Antibodies in Immuno-Oncology and Beyond: Challenges, Perspectives, and Prospects
Article
S.F. Oosting, J. Barriuso, A. Bottomley, M. Galotti, B. Gyawali, B. Kiesewetter, N.J. Latino, F. Martinelli, M. Pe, G. Pentheroudakis, F. Roitberg, H. Vachon, E.G.E. de Vries, M. Piccart, N.I. Cherny
Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale
Article
Doreen A. Ezeife MD, Francois Dionne PhD, Aline Fusco Fares MD, Ellen Laura Rose Cusano MD, Rouhi Fazelzad BSc, MISt, Wenzie Ng BSc, MPharm, RPh, Don Husereau BSc Pharm, MSc, Farzad Ali BPharm, MSc, Christina Sit MSc, Barry Stein B.Com BCL, LLB, Jennifer
Value assessment of oncology drugs using a weighted criterion-based approach
Article
Jaques van Heerden, MD, Mohamed Zaghloul, MD, Anouk Neven, MSc, Teresa de Rojas, MD, PhD, Jennifer Geel, MD, Catherine Patte, MD, Joyce Balagadde-Kambugu, MD, Peter Hesseling, MD, Francine Tchintseme, MD, Eric Bouffet, MD, and Laila Hessissen, MD